{"id":"NCT00149734","sponsor":"University of Colorado, Denver","briefTitle":"Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia","officialTitle":"Atypical Antipsychotics and P50 Sensory Gating","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-01","primaryCompletion":"2010-05","completion":"2010-05","firstPosted":"2005-09-08","resultsPosted":"2021-08-13","lastUpdate":"2021-08-13"},"enrollment":8,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Ondansetron followed by placebo","otherNames":["Zofran, Zuplenz"]},{"type":"DRUG","name":"Placebo followed by Ondansetron","otherNames":["Zofran, Zuplenz"]}],"arms":[{"label":"Ondansetron followed by placebo","type":"EXPERIMENTAL"},{"label":"Placebo followed by Ondansetron","type":"EXPERIMENTAL"}],"summary":"This study will examine the effects of ondansetron on auditory nerve activity in people with schizophrenia who are being treated with new antipsychotics.","primaryOutcome":{"measure":"P50 Sensory Gating","timeFrame":"Up to 3 hours","effectByArm":[{"arm":"Ondansetron","deltaMin":41.4,"sd":39.7},{"arm":"Placebo","deltaMin":80.2,"sd":21.3}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["15677607","15465979"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":0},"commonTop":[]}}